Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: J Health Econ. 2012 May 9;31(4):630–643. doi: 10.1016/j.jhealeco.2012.04.006

Table G.1.

Pharmacotherapy Cohort Simulation Results

Current Eligibility Expanded Eligibility
Baseline Intervention Effect Baseline Intervention Effect

Disability free life expectancy 21.94 22.09 0.16 22.78 22.82 0.04
Life expectancy 29.68 29.76 0.09 29.64 29.67 0.04
Medical costs ($2010)
    Medicare 133 845 133 684 −161 123 610 123 400 −210
    Medicaid 50 117 50 095 −22 45 877 45 825 −52
    Private Medical Cost 162 745 162 585 −160 151 983 151 783 −200
Total 346 707 346 364 −343 321 470 321 007 −462
Other fiscal outcomes ($2010)
 Tax Revenue 79 426 79 534 107 84 092 84 134 41
 SSI, DI, OASI 125 162 125 517 355 134 154 134 320 166
 Earnings 231 060 231 360 300 238 000 238 091 91

Notes: averages from 1000 simulations of the projection for a cohort entering at age 50 in 2010. Real discount rate is 3%. All amounts in $2010 dollars. SSI = Supplemental Security Income, DI = Disability insurance, OASI = old-age social insurance. Private medical costs cover other costs not covered by Medicare and Medicaid (e.g. costs covered by employer). Please refer to text for definition of current and expanded eligibility.